Ferring, Blackstone to invest $570m in gene therapy for bladder cancer

This article was originally published here

In this connection, Ferring Pharmaceuticals has launched a new company FerGene, which will focus on the global development and US commercialisation of nadofaragene firadenovec. The gene therapy is

The post Ferring, Blackstone to invest $570m in gene therapy for bladder cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply